These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 29885931)

  • 1. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
    Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
    Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.
    Freedman BI; Langefeld CD; Andringa KK; Croker JA; Williams AH; Garner NE; Birmingham DJ; Hebert LA; Hicks PJ; Segal MS; Edberg JC; Brown EE; Alarcón GS; Costenbader KH; Comeau ME; Criswell LA; Harley JB; James JA; Kamen DL; Lim SS; Merrill JT; Sivils KL; Niewold TB; Patel NM; Petri M; Ramsey-Goldman R; Reveille JD; Salmon JE; Tsao BP; Gibson KL; Byers JR; Vinnikova AK; Lea JP; Julian BA; Kimberly RP;
    Arthritis Rheumatol; 2014 Feb; 66(2):390-6. PubMed ID: 24504811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
    Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
    Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy.
    Bostrom MA; Kao WH; Li M; Abboud HE; Adler SG; Iyengar SK; Kimmel PL; Hanson RL; Nicholas SB; Rasooly RS; Sedor JR; Coresh J; Kohn OF; Leehey DJ; Thornley-Brown D; Bottinger EP; Lipkowitz MS; Meoni LA; Klag MJ; Lu L; Hicks PJ; Langefeld CD; Parekh RS; Bowden DW; Freedman BI;
    Am J Kidney Dis; 2012 Feb; 59(2):210-21. PubMed ID: 22119407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of Association of the APOL1 G3 Haplotype in African Americans with ESRD.
    Palmer ND; Ng MC; Langefeld CD; Divers J; Lea JP; Okusa MD; Kimberly RP; Bowden DW; Freedman BI
    J Am Soc Nephrol; 2015 May; 26(5):1021-5. PubMed ID: 25249559
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Chung CP; Karakoc G; Dickson A; Liu G; Gamboa JL; Mosley JD; Cox NJ; Kawai VK
    Lupus; 2023 May; 32(6):763-770. PubMed ID: 37105192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.
    Ma L; Langefeld CD; Comeau ME; Bonomo JA; Rocco MV; Burkart JM; Divers J; Palmer ND; Hicks PJ; Bowden DW; Lea JP; Krisher JO; Clay MJ; Freedman BI
    Kidney Int; 2016 Aug; 90(2):389-395. PubMed ID: 27157696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
    Anyaegbu EI; Shaw AS; Hruska KA; Jain S
    Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Genetic Testing for APOL1: Are we There Yet?
    Young BA; Fullerton SM; Wilson JG; Cavanaugh K; Blacksher E; Spigner C; Himmelfarb J; Burke W
    Semin Nephrol; 2017 Nov; 37(6):552-557. PubMed ID: 29110763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.
    Hicks PJ; Langefeld CD; Lu L; Bleyer AJ; Divers J; Nachman PH; Derebail VK; Bowden DW; Freedman BI
    Kidney Int; 2011 Dec; 80(12):1339-43. PubMed ID: 21849968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target organ damage in African American hypertension: role of APOL1.
    Freedman BI; Murea M
    Curr Hypertens Rep; 2012 Feb; 14(1):21-8. PubMed ID: 22068337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.
    Freedman BI; Kopp JB; Langefeld CD; Genovese G; Friedman DJ; Nelson GW; Winkler CA; Bowden DW; Pollak MR
    J Am Soc Nephrol; 2010 Sep; 21(9):1422-6. PubMed ID: 20688934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coding variants in nephrin (NPHS1) and susceptibility to nephropathy in African Americans.
    Bonomo JA; Ng MC; Palmer ND; Keaton JM; Larsen CP; Hicks PJ; ; Langefeld CD; Freedman BI; Bowden DW
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1434-40. PubMed ID: 24948143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
    Freedman BI; Langefeld CD; Lu L; Divers J; Comeau ME; Kopp JB; Winkler CA; Nelson GW; Johnson RC; Palmer ND; Hicks PJ; Bostrom MA; Cooke JN; McDonough CW; Bowden DW
    PLoS Genet; 2011 Jun; 7(6):e1002150. PubMed ID: 21698141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Analysis of the Cubilin (CUBN) and Megalin (LRP2) Genes with ESRD in African Americans.
    Ma J; Guan M; Bowden DW; Ng MCY; Hicks PJ; Lea JP; Ma L; Gao C; Palmer ND; Freedman BI
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):1034-1043. PubMed ID: 27197912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.
    Young BA; Blacksher E; Cavanaugh KL; Freedman BI; Fullerton SM; Kopp JB; Umeukeje EM; West KM; Wilson JG; Burke W;
    Am J Nephrol; 2019; 50(4):303-311. PubMed ID: 31480040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.
    Freedman BI; Langefeld CD; Turner J; Núñez M; High KP; Spainhour M; Hicks PJ; Bowden DW; Reeves-Daniel AM; Murea M; Rocco MV; Divers J
    Kidney Int; 2012 Oct; 82(7):805-11. PubMed ID: 22695330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
    Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
    Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.
    Chen TK; Choi MJ; Kao WH; Astor BC; Scialla JJ; Appel LJ; Li L; Lipkowitz MS; Wolf M; Parekh RS; Winkler CA; Estrella MM; Crews DC
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2128-35. PubMed ID: 26430087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.